Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JEANIE L COTE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1467771311
CMS profile
405003
Location
OWOSSO, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$108,215.99

202 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JEANIE L COTE

NPI 1467771311 · CMS profile ID 405003

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

OWOSSO, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1467771311?year=2024&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JEANIE L COTE, NPI 1467771311, CMS profile ID 405003. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1467771311?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JEANIE L COTE, NPI 1467771311, CMS profile ID 405003. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1467771311?year=2024&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JEANIE L COTE, NPI 1467771311, CMS profile ID 405003, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 5; records 151–200 of 202 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1467771311?year=2024&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

202 matching records · $108,215.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 202 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 202.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $69.4903/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120239916 CMS
ABBVIE INC. $8.5803/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506604 CMS
MITSUBISHI TANABE PHARMA AMERICA, INC. $26.9203/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144507202 CMS
TG Therapeutics, Inc. $2,200.0003/14/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887720 CMS
TG Therapeutics, Inc. $116.8603/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887758 CMS
GENZYME CORPORATION $22.9303/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139838497 CMS
ABBVIE INC. $6.6903/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506602 CMS
Merz Pharmaceuticals, LLC $29.1403/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137950192 CMS
ABBVIE INC. $5.0302/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506600 CMS
TG Therapeutics, Inc. $800.0002/23/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136887736 CMS
Celgene Corporation $11.6502/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149537 CMS
Celgene Corporation $350.1102/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149569 CMS
E.R. Squibb & Sons, L.L.C. $181.5702/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101516043 CMS
E.R. Squibb & Sons, L.L.C. $168.5402/22/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101516047 CMS
ABBVIE INC. $8.1302/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506598 CMS
PFIZER INC. $16.0902/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1131498053 CMS
Biogen, Inc. $22.6402/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104807501 CMS
Celgene Corporation $2,400.0002/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149571 CMS
EMD Serono, Inc. $21.1602/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120233050 CMS
ABBVIE INC. $1.2802/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506594 CMS
ABBVIE INC. $11.0002/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506596 CMS
Kyowa Kirin, Inc. $24.7402/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127032303 CMS
Biogen, Inc. $82.4202/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104805241 CMS
Biogen, Inc. $3,384.0002/08/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104862322 CMS
EMD Serono, Inc. $6.1502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120233048 CMS
ABBVIE INC. $6.2002/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506592 CMS
Biogen, Inc. $19.3102/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104809715 CMS
ABBVIE INC. $14.4902/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506590 CMS
Lilly USA, LLC $16.9301/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135007431 CMS
ABBVIE INC. $20.8701/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506588 CMS
Novartis Pharmaceuticals Corporation $2.4201/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619003 CMS
ABBVIE INC. $8.1501/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506586 CMS
Celgene Corporation $32.7101/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149541 CMS
Celgene Corporation $32.7101/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149543 CMS
Celgene Corporation $54.5301/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149545 CMS
Celgene Corporation $32.7201/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149547 CMS
Celgene Corporation $869.4401/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149549 CMS
Celgene Corporation $315.2701/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101149551 CMS
ABBVIE INC. $6.6801/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506584 CMS
Averitas Pharma Inc. $14.1801/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133422610 CMS
Lilly USA, LLC $18.0601/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135056214 CMS
Novartis Pharmaceuticals Corporation $31.1001/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619005 CMS
Novartis Pharmaceuticals Corporation $1,057.5001/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619009 CMS
Biogen, Inc. $97.0001/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104842884 CMS
Biogen, Inc. $2,538.0001/12/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104849722 CMS
EMD Serono, Inc. $298.0001/11/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120215224 CMS
Novartis Pharmaceuticals Corporation $7.7901/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619007 CMS
Novartis Pharmaceuticals Corporation $1,057.5001/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086619011 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.1401/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137519771 CMS
ABBVIE INC. $8.3101/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103506582 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $13,275.10 47
PY2020 $21,937.00 57
PY2021 $26,522.67 38
PY2022 $42,657.54 142
PY2023 $101,378.02 241
PY2024 $108,215.99 202
PY2025 $249,062.06 283

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $2,493.40 1
PY2025 Principal investigator $321,378.76 70
PY2024 Principal investigator $189,437.17 45
PY2023 Recipient $2,028.52 1
PY2023 Principal investigator $638,958.70 48
PY2022 Principal investigator $98,013.39 30
PY2021 Principal investigator $32,232.73 2
PY2019 Recipient $1,058.64 11

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199259
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/19/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199257
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/19/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199261
Principal investigator 1 Novartis Pharmaceuticals Corporation $13,467.54 12/17/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE CENTER
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190307177
Principal investigator 1 TG Therapeutics, Inc. $25.00 12/17/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199255
Principal investigator 1 TG Therapeutics, Inc. $20,775.00 11/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199245
Principal investigator 1 TG Therapeutics, Inc. $25.00 11/26/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199253
Principal investigator 1 TG Therapeutics, Inc. $25.00 11/26/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199263
Principal investigator 1 Genentech, Inc. $2,500.00 11/10/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666622
Principal investigator 1 Genentech, Inc. $675.00 11/05/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666619
Principal investigator 1 TG Therapeutics, Inc. $9,150.00 11/01/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199243
Principal investigator 1 TG Therapeutics, Inc. $25.00 10/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199251
Principal investigator 1 TG Therapeutics, Inc. $25.00 10/16/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199249
Principal investigator 1 TG Therapeutics, Inc. $25.00 10/15/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199247
Principal investigator 1 TG Therapeutics, Inc. $18,025.00 09/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199371
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199203
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199209
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199211
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199213
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199215
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199217
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/29/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199219
Principal investigator 1 TG Therapeutics, Inc. $25.00 09/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199201
Principal investigator 1 TG Therapeutics, Inc. $9,900.00 08/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199369
Principal investigator 1 TG Therapeutics, Inc. $25.00 08/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199199
Principal investigator 1 TG Therapeutics, Inc. $25.00 08/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199207
Principal investigator 1 Hoffmann-La Roche Limited $1,346.00 08/14/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623573
Principal investigator 1 Hoffmann-La Roche Limited $500.00 08/05/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623568
Principal investigator 1 TG Therapeutics, Inc. $25.00 07/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199197
Principal investigator 1 TG Therapeutics, Inc. $25.00 07/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199205
Principal investigator 1 TG Therapeutics, Inc. $3,325.00 07/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199367
Principal investigator 1 Hoffmann-La Roche Limited $500.00 07/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623563
Principal investigator 1 Hoffmann-La Roche Limited $194.00 07/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623577
Principal investigator 1 Hoffmann-La Roche Limited $500.00 07/15/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623582
Principal investigator 1 TG Therapeutics, Inc. $25.00 06/16/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199331
Principal investigator 1 TG Therapeutics, Inc. $18,100.00 06/01/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199329
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199325
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199347
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199349
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/30/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199351
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199323
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199341
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199343
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/28/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199345
Principal investigator 1 TG Therapeutics, Inc. $25.00 05/23/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199321
Principal investigator 1 Hoffmann-La Roche Limited $500.00 05/13/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623549
Principal investigator 1 Hoffmann-La Roche Limited $2,308.00 05/13/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623553
Principal investigator 1 Hoffmann-La Roche Limited $2,308.00 05/08/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623557
Principal investigator 1 Genentech, Inc. $2,874.00 05/02/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666609
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199319
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199315
Principal investigator 1 TG Therapeutics, Inc. $975.00 04/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199317
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/22/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199339
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/21/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199313
Principal investigator 1 TG Therapeutics, Inc. $25.00 04/21/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199337
Principal investigator 1 Genentech, Inc. $77.06 04/17/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666605
Principal investigator 1 Genentech, Inc. $72.27 04/03/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666616
Principal investigator 1 Hoffmann-La Roche Limited $500.00 04/01/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623560
Recipient F. Hoffmann-La Roche AG $2,493.40 03/31/2025 Covered Recipient Physician Switch From Eculizumab to Satralizumab in Aquaporin 4 Immunoglobulin G–Seropositive Neuromyelitis Optica Spectrum Disorder: A Case Series Report No dispute reported 06/30/2026 1211536374
Principal investigator 1 TG Therapeutics, Inc. $6,500.00 03/31/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199307
Principal investigator 1 TG Therapeutics, Inc. $57,764.48 03/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199327
Principal investigator 1 Genentech, Inc. $750.00 03/20/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666612
Principal investigator 1 Hoffmann-La Roche Limited $2,980.00 02/20/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE
Ocrelizumab breast milk transfer stud No dispute reported 06/30/2026 1211623546
Principal investigator 1 Novartis Pharmaceuticals Corporation $126,562.49 02/19/2025 Non-covered Recipient Entity
MEMORIAL HEALTHCARE CENTER
A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse No dispute reported 06/30/2026 1190307179
Principal investigator 1 Genentech, Inc. $6,131.00 02/04/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666601
Principal investigator 1 TG Therapeutics, Inc. $9,675.00 02/01/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199305
Principal investigator 1 TG Therapeutics, Inc. $25.00 01/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199311
Principal investigator 1 TG Therapeutics, Inc. $25.00 01/24/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199335
Principal investigator 1 Genentech, Inc. $18.92 01/23/2025 Non-covered Recipient Entity
THE MEMORIAL HOSPITAL MEMORIAL HEALTHCARE
Ocrelizumab SC Phase III No dispute reported 06/30/2026 1211666598
Principal investigator 1 TG Therapeutics, Inc. $25.00 01/08/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199309
Principal investigator 1 TG Therapeutics, Inc. $1,450.00 01/06/2025 Non-covered Recipient Entity
Memorial Healthcare
(ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study No dispute reported 06/30/2026 1226199303